Market Cap | 78.41M | P/E | - | EPS this Y | 44.90% | Ern Qtrly Grth | - |
Income | -96.02M | Forward P/E | -1.23 | EPS next Y | -4.10% | 50D Avg Chg | -27.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -32.00% |
Dividend | N/A | Price/Book | 0.43 | EPS next 5Y | - | 52W High Chg | -72.00% |
Recommedations | 2.00 | Quick Ratio | 8.52 | Shares Outstanding | 37.76M | 52W Low Chg | 18.00% |
Insider Own | 0.79% | ROA | -30.67% | Shares Float | 18.01M | Beta | 1.94 |
Inst Own | 75.95% | ROE | -56.79% | Shares Shorted/Prior | 0.92M/633.55K | Price | 4.00 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 21,696 | Target Price | 17.00 |
Oper. Margin | - | Earnings Date | May 9 | Volume | 8,992 | Change | -3.15% |
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
William Blair | Outperform | Mar 28, 24 |
Barclays | Overweight | Mar 18, 24 |
Citigroup | Buy | Mar 15, 24 |
HC Wainwright & Co. | Buy | Mar 14, 24 |
Piper Sandler | Overweight | Mar 14, 24 |
HC Wainwright & Co. | Buy | Mar 11, 24 |
HC Wainwright & Co. | Buy | Dec 8, 23 |
Cantor Fitzgerald | Overweight | Sep 22, 23 |
Barclays | Overweight | Nov 11, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Ganot Ilan | Director Director | Jan 27 | Sell | 7.99 | 139 | 1,111 | 8,416 | 01/30/24 |
PERCEPTIVE ADVISORS LLC | Director Director | Jan 11 | Buy | 5.53 | 3,410,713 | 18,861,243 | 6,833,539 | 01/12/24 |
RA CAPITAL MANAGEMENT, L.P. | Director Director | Jan 11 | Buy | 5.53 | 904,160 | 5,000,005 | 4,192,216 | 01/12/24 |
Tan Kevin | CFO & Treasurer CFO & Treasurer | Jan 09 | Sell | 8.2 | 3,935 | 32,267 | 9,308 | 01/11/24 |
Ganot Ilan | Director Director | Jan 03 | Sell | 5.3 | 1,142 | 6,053 | 8,167 | 01/05/24 |
Ganot Ilan | Director Director | May 02 | Sell | 4.85 | 487 | 2,362 | 4,153 | 06/08/23 |
Morris Carl Ashley | Chief Scientific Off.. Chief Scientific Officer | Jan 27 | Sell | 7.49 | 441 | 3,303 | 19,760 | 01/31/23 |
Ganot Ilan | Director Director | Jan 27 | Sell | 7.49 | 1,523 | 11,407 | 84,591 | 01/31/23 |
Morris Carl Ashley | Chief Scientific Off.. Chief Scientific Officer | Mar 14 | Sell | 1.1 | 22,665 | 24,932 | 255,209 | 03/15/22 |
Schneider Joel Solomon Zev | Chief Operating Offi.. Chief Operating Officer | Mar 14 | Sell | 1.1 | 30,504 | 33,554 | 236,270 | 03/15/22 |